Idylla IFV-RSV Panel Clinical Testing

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

NCT07128121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

NCT04068792 ·Status: COMPLETED ·Phase: PHASE2

RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.

NCT01805921 ·Status: COMPLETED ·Phase: PHASE1

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

NCT06251024 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02794870 ·Status: COMPLETED ·Phase: PHASE1

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

NCT02508194 ·Status: TERMINATED ·Phase: PHASE2

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

NCT06237296 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

NCT03502707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

NCT05083585 ·Status: COMPLETED ·Phase: PHASE3

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

NCT00578682 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

NCT02561871 ·Status: COMPLETED ·Phase: PHASE1

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

NCT04785612 ·Status: COMPLETED ·Phase: PHASE2

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

NCT04221412 ·Status: NO_LONGER_AVAILABLE

RSV Challenge in Healthy Adults

NCT00100373 ·Status: COMPLETED ·Phase: NA

Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults

NCT06890429 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

NCT06473519 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

NCT03916185 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

NCT06067230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

NCT03227029 ·Status: COMPLETED ·Phase: PHASE1

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

NCT04752644 ·Status: COMPLETED ·Phase: PHASE2